Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
<p>Abstract</p> <p>Background</p> <p>RRM1 and ERCC1 overexpression has been extensively investigated as potential predictive markers of tumor sensitivity to conventional chemotherapy agents, most thoroughly in lung cancer. However, data in pancreatic cancer are scarce.&...
Main Authors: | Valsecchi Matias E, Holdbrook Thomas, Leiby Benjamin E, Pequignot Edward, Littman Susan J, Yeo Charles J, Brody Jonathan R, Witkiewicz Agnieszka K |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/12/104 |
Similar Items
-
Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection
by: Min SONG, et al.
Published: (2009-05-01) -
Clinical Perspectives of ERCC1 in Bladder Cancer
by: Konstantinos Koutsoukos, et al.
Published: (2020-11-01) -
Function and Interactions of ERCC1-XPF in DNA Damage Response
by: Maryam Faridounnia, et al.
Published: (2018-12-01) -
Expression of Genomic Instability-Related Molecules: Cyclin F, RRM2 and SPDL1 and Their Prognostic Significance in Pancreatic Adenocarcinoma
by: Anna Klimaszewska-Wiśniewska, et al.
Published: (2021-02-01) -
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma
by: Benjamin E Leiby, et al.
Published: (2023-10-01)